Allianz SE Buys New Position in BioNTech SE (NASDAQ:BNTX)

Allianz SE purchased a new position in BioNTech SE (NASDAQ:BNTX) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 800 shares of the company’s stock, valued at approximately $90,000.

Several other large investors also recently bought and sold shares of BNTX. Charles Schwab Investment Management Inc. boosted its stake in shares of BioNTech by 123.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock valued at $15,919,000 after purchasing an additional 74,119 shares during the period. SG Americas Securities LLC boosted its position in BioNTech by 412.3% in the 4th quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock valued at $4,726,000 after buying an additional 33,375 shares during the last quarter. Mirabaud & Cie SA acquired a new stake in shares of BioNTech during the fourth quarter valued at about $684,000. Redmile Group LLC purchased a new stake in shares of BioNTech during the third quarter worth about $18,345,000. Finally, Vestcor Inc acquired a new position in shares of BioNTech in the third quarter worth about $784,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Trading Down 4.1 %

BioNTech stock opened at $91.06 on Tuesday. The firm has a 50-day moving average price of $110.99 and a two-hundred day moving average price of $113.65. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The firm has a market capitalization of $21.85 billion, a price-to-earnings ratio of -43.36 and a beta of 0.30. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same period in the prior year, the company posted $1.90 EPS. The business’s revenue for the quarter was down 19.5% compared to the same quarter last year. Sell-side analysts expect that BioNTech SE will post -3.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

BNTX has been the subject of a number of recent analyst reports. Morgan Stanley lowered their price objective on BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a research note on Tuesday, March 11th. Canaccord Genuity Group reissued a “buy” rating and set a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Truist Financial began coverage on shares of BioNTech in a report on Friday, January 10th. They issued a “buy” rating and a $172.00 price target on the stock. Citigroup started coverage on shares of BioNTech in a report on Thursday, March 13th. They set a “buy” rating and a $145.00 price objective for the company. Finally, Wells Fargo & Company began coverage on shares of BioNTech in a research note on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 target price on the stock. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $143.73.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.